Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy

Journal of Clinical Oncology

Volumn 28, Issue 8, 2010, Pages 1415-1421

  Cerci, Juliano J ^a   Trindade, Evelinda ^a   Pracchia, Luís F ^a   Pitella, Felipe A ^a   Linardi, Camila C G ^a   Soares Jr , José ^a   Delbeke, Dominique ^a   Topfer, Leigh Ann ^a   Buccheri, Valeria ^a   Meneghetti, José C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DIAGNOSTIC ACCURACY; FOLLOW UP; HEALTH CARE COST; HODGKIN DISEASE; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; SENSITIVITY AND SPECIFICITY; BRAZIL; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; FEMALE; MULTIMODALITY CANCER THERAPY; SCINTISCANNING; SURVIVAL;

ADULT; BRAZIL; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HEALTH CARE COSTS; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77950465811     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.4367     Document Type: Article

References (28)

1. Juweid ME, Stroobants S, Hoekstra OS, et al: Use of positron emission tomography for response assessment of lymphoma: Consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 25:571-578, 2007 (Pubitemid 350002965)
2. Isasi CR, Ping L, Blafoux D: A metaanalysis of 18F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066-1074, 2005 (Pubitemid 41170236)
3. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al: 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review. Haematologica 91:522-529, 2006
4. Facey K, Bradbury I, Laking G, et al: Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11:iii-iv, xi-267, 2007
5. Spaepen K, Stroobants S, Dupont P, et al: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419, 2001
6. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999 (Pubitemid 29323856)
7. Kobe C, Dietlein M, Franklin J, et al: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989-3994, 2008
8. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al: 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: Comparison with CT. Leuk Lymphoma 39:543-553, 2000 (Pubitemid 32162393)
9. Weihrauch MR, Re D, Scheidhauer K, et al: Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930-2934, 2001
10. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas. J Clin Oncol 17:1244, 1999
11. Weber WA: Assessing tumor response to therapy. J Nucl Med 50:1S-10S, 2009 (suppl 1)
12. Castagna L, Bramanti S, Balzarotti M, et al: Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 145:369-372, 2009
13. Oza AM, Ganesan TS, Leahy M, et al: Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. Ann Oncol 4:385-392, 1993 (Pubitemid 23193103)
14. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
15. Juweid ME, Cheson BD: Role of positron emission tomography in lymphoma. J Clin Oncol 23:4577-4580, 2005 (Pubitemid 46224057)
16. Juweid ME, Cheson BD: Positron emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507, 2006 (Pubitemid 43200300)
17. Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931-933, 1988
18. Poulou LS, Karianakis G, Ziakas PD: FDG PET scan strategies and long-term outcomes after firstline therapy in Hodgkin's disease. Eur J Radiol 70:499-506, 2009
19. Jerusalem G, Hustinx R, Beguin Y, et al: Evaluation of therapy for lymphoma. Semin Nucl Med 35:186-196, 2005 (Pubitemid 41138137)
20. Castellucci P, Nanni C, Farsad M, et al: Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: Prevalence and scan interpretation. Nucl Med Commun 26:689-694, 2005 (Pubitemid 41073369)
21. Dittman H, Sokler M, Kollmannsberger C, et al: Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 8:1393-1399, 2001 (Pubitemid 33758754)
22. Cerci JJ, Pracchia LF, Soares-Junior J, et al: Positron emission tomography with 2-[18f]-fluoro-2-deoxy-D-glucose for initial staging of Hodgkin lymphoma: A single center experience in Brazil. Clinics (Sao Paulo) 64:491-498, 2009
23. Sebastianes FM, Cerci JJ, Zanoni PH, et al: Role of 18F- fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 92:4485-4488, 2007 (Pubitemid 350074775)
24. Remonnay R, Morelle M, Pommier P, et al: Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making. Int J Technol Assess Health Care 24:212-220, 2008 (Pubitemid 351522735)
25. Bradbury I, Bonell E, Boynton J, et al: Health Technology Assessment Report 2: Positron emission tomography (PET) imaging in cancer management. Report No. 1903961319. Glasgow, Scotland, Health Technology Board for Scotland, 2002
26. Nishizawa S, Kojima S, Teramukai S, et al: Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: A preliminary report. J Clin Oncol 27:1767-1773, 2009
27. Tarride JE, Blackhouse G, Bischof M, et al: Approaches for economic evaluations of health care technologies. J Am Coll Radiol 6:307-316, 2009
28. Hutchings M, Loft A, Hansen M, et al: Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 91:482-489, 2006